cGKI alpha Inhibitors
Items 1 to 10 of 22 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(D) DT-2 | sc-361974 | 500 µg | $364.00 | |||
(D) DT-2 is a selective cGKI alpha modulator characterized by its unique structural features that promote specific molecular interactions. Its design allows for enhanced receptor affinity, leading to distinct activation pathways that influence intracellular signaling. The compound exhibits remarkable stability under physiological conditions, facilitating efficient cellular uptake. Additionally, its unique functional groups contribute to altered reaction kinetics, enhancing its efficacy in modulating cGKI alpha activity. | ||||||
Rp-8-Br-PET-cyclic GMPS, Sodium Salt | 172806-20-1 | sc-203989 | 1 µmol | $165.00 | ||
Rp-8-Br-PET-cyclic GMPS, Sodium Salt is a selective modulator of cGKI alpha, distinguished by its cyclic structure that promotes unique conformational dynamics. This compound engages in specific interactions with target proteins, influencing downstream signaling cascades. Its sodium salt form enhances solubility, allowing for improved bioavailability. The compound's distinct electronic properties facilitate rapid reaction kinetics, optimizing its role in cellular signaling pathways. | ||||||
KT5823 | 126643-37-6 | sc-3534 sc-3534A sc-3534B | 100 µg 1 mg 5 mg | $182.00 $1228.00 $4895.00 | 21 | |
A selective inhibitor of PKG1 that binds to the ATP binding site, reducing its kinase activity and subsequent signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, modulates AKT signaling, potentially influencing cGKIα. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil works like Sildenafil, it inhibits phosphodiesterase 5, increasing cellular cGMP levels, which activates PKG1 by cGMP-dependent allosteric changes. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Tadalafil selectively inhibits PDE5, resulting in raised cGMP concentrations and subsequent activation of PKG1 via cGMP binding and allosteric modulation. | ||||||
Riociguat | 625115-55-1 | sc-476845 | 5 mg | $300.00 | ||
Riociguat sensitizes soluble guanylyl cyclase to endogenous nitric oxide, increasing cGMP synthesis and thereby potentiating PKG1 activation. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
A PKC inhibitor, modulates protein kinase C pathways, potentially influencing cGKIα. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
A calcium-dependent PKC inhibitor, affects intracellular calcium signaling, potentially impacting cGKIα. | ||||||
Hydralazine-15N4 Hydrochloride | 304-20-1 (unlabeled) | sc-490605 | 1 mg | $480.00 | ||
Hydralazine may induce nitric oxide release, which can increase cGMP levels and subsequently enhance the activation of PKG1. | ||||||